JUBILANT PHARMOVA Financial Statement Analysis
|
||
The Revenues of JUBILANT PHARMOVA have increased by 2.47% YoY .
The Earnings Per Share (EPS) of JUBILANT PHARMOVA has increased by Positive YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
JUBILANT PHARMOVA Last 5 Annual Financial Results
[BOM: 530019|NSE : JUBLPHARMA]
Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
---|---|---|---|---|---|
Revenues | ₹6,282 Cr | ₹6,130 Cr | ₹6,099 Cr | ₹5,976 Cr | ₹9,111 Cr |
Expenses | ₹5,506 Cr | ₹4,974 Cr | ₹4,702 Cr | ₹4,428 Cr | ₹7,372 Cr |
Operating Profit (Excl OI) | ₹776 Cr | ₹1,156 Cr | ₹1,396 Cr | ₹1,548 Cr | ₹1,739 Cr |
Other Income | ₹38 Cr | ₹11 Cr | ₹18 Cr | ₹37 Cr | ₹36 Cr |
Interest | ₹188 Cr | ₹145 Cr | ₹184 Cr | ₹200 Cr | ₹220 Cr |
Depreciation | ₹554 Cr | ₹382 Cr | ₹349 Cr | ₹340 Cr | ₹371 Cr |
Profit Before Tax | ₹28 Cr | ₹630 Cr | ₹871 Cr | ₹1,013 Cr | ₹904 Cr |
Profit After Tax | ₹-65 Cr | ₹413 Cr | ₹574 Cr | ₹678 Cr | ₹577 Cr |
Consolidated Net Profit | ₹-61 Cr | ₹414 Cr | ₹836 Cr | ₹898 Cr | ₹574 Cr |
Earnings Per Share (Rs) | ₹4.88 | ₹-3.84 | ₹26.01 | ₹52.51 | ₹56.39 |
PAT Margin (%) | 1.08 | -1.03 | 6.74 | 9.41 | 11.34 |
ROE(%) | 1.34 | -1.21 | 8.21 | 11.09 | 13.02 |
ROCE(%) | 5.02 | 2.53 | 9.97 | 12.02 | 12.20 |
Total Debt/Equity(x) | 0.63 | 0.63 | 0.55 | 0.55 | 0.83 |
Key Financials |
||
Market Cap | : | ₹ 14,087.7 Cr |
Revenue (TTM) | : | ₹ 7,064.3 Cr |
Net Profit(TTM) | : | ₹ 620.2 Cr |
EPS (TTM) | : | ₹ 38.9 |
P/E (TTM) | : | 22.7 |
Industry Peers & Returns | 1W | 1M | 1Y |
JUBILANT PHARMOVA | -3.3% | -1.3% | 60.6% |
SUN PHARMACEUTICAL INDUSTRIES | -1.7% | 5.5% | 5.4% |
DIVIS LABORATORIES | -5.2% | -4.6% | 49% |
CIPLA | -4.2% | -2.4% | -3.8% |
TORRENT PHARMACEUTICALS | 1.6% | 8.4% | 26.9% |
DR REDDYS LABORATORIES | -5.5% | -3.4% | -9.4% |
MANKIND PHARMA | -3.2% | 3.9% | 5% |
ZYDUS LIFESCIENCES | -4.6% | -5.6% | -12.2% |
LUPIN | -1.7% | -4.3% | 22.8% |
JUBILANT PHARMOVA Revenues
[BOM: 530019|NSE : JUBLPHARMA]
Y-o-Y | 2.47 % |
5 Yr CAGR | -8.88 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2024 | ₹6,282 Cr | 2.47 | |
Mar2023 | ₹6,130 Cr | 0.52 | |
Mar2022 | ₹6,099 Cr | 2.05 | |
Mar2021 | ₹5,976 Cr | -34.41 | |
Mar2020 | ₹9,111 Cr | - |
JUBILANT PHARMOVA Operating Profit
[BOM: 530019|NSE : JUBLPHARMA]
Y-o-Y | -32.87 % |
5 Yr CAGR | -18.26 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2024 | ₹776 Cr | -32.87 | |
Mar2023 | ₹1,156 Cr | -17.20 | |
Mar2022 | ₹1,396 Cr | -9.79 | |
Mar2021 | ₹1,548 Cr | -10.99 | |
Mar2020 | ₹1,739 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -34.46 % |
5 Yr CAGR | -10.30 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2024 | 12.36% | -34.46 | |
Mar2023 | 18.86% | -17.64 | |
Mar2022 | 22.9% | -11.58 | |
Mar2021 | 25.9% | 35.67 | |
Mar2020 | 19.09% | - |
JUBILANT PHARMOVA Profit After Tax
[BOM: 530019|NSE : JUBLPHARMA]
Y-o-Y | Negative |
5 Yr CAGR | Negative |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2024 | ₹-61 Cr | Negative | |
Mar2023 | ₹414 Cr | -50.48 | |
Mar2022 | ₹836 Cr | -6.94 | |
Mar2021 | ₹898 Cr | 56.36 | |
Mar2020 | ₹574 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | Positive |
5 Yr CAGR | -44.45 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2024 | 1.08 % | Positive | |
Mar2023 | -1.03 % | Negative | |
Mar2022 | 6.74 % | -28.37 | |
Mar2021 | 9.41 % | -17.02 | |
Mar2020 | 11.34 % | - |
JUBILANT PHARMOVA Earnings Per Share (EPS)
[BOM: 530019|NSE : JUBLPHARMA]
Y-o-Y | Positive |
5 Yr CAGR | -45.76 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2024 | ₹4.88 | Positive | |
Mar2023 | ₹-3.84 | Negative | |
Mar2022 | ₹26 | -50.47 | |
Mar2021 | ₹53 | -6.88 | |
Mar2020 | ₹56 | - |
JUBILANT PHARMOVA Return on Capital Employed (ROCE)
[BOM: 530019|NSE : JUBLPHARMA]
Y-o-Y | 98.42 % |
5 Yr CAGR | -19.91 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2024 | 5.02% | 98.42 | |
Mar2023 | 2.53% | -74.62 | |
Mar2022 | 9.97% | -17.05 | |
Mar2021 | 12.02% | -1.48 | |
Mar2020 | 12.2% | - |
JUBILANT PHARMOVA Share Price vs Sensex
Current Share Price | : | ₹884.4 |
Current MarketCap | : | ₹ 14,087.7 Cr |
Updated EOD on | : | Apr 07,2025 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
JUBILANT PHARMOVA | -3.3% |
-1.3% |
60.6% |
SENSEX | -5.5% |
0.2% |
-1% |
JUBILANT PHARMOVA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
BSE ALLCAP | NA | 7% | 4.8% |
BSE MIDSMALLCAP | -2.6% | 6% | 2.3% |
BSE 500 SHARIAH | -4.7% | 1.4% | -5.7% |
BSE HEALTHCARE | -5.2% | 1.8% | 10.7% |
BSE 500 | -5.7% | 0.9% | -2.6% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY 500 EQUAL WEIGHT | -5.7% | 1.5% | NA |
NIFTY TOTAL MARKET | -5.8% | 0.9% | -2.3% |
NIFTY 500 | -5.8% | 0.9% | -2.3% |
NIFTY MIDSMALL HEALTHCARE | -5.8% | 2% | 16% |
NIFTY500 MULTICAP 50:25:25 | -5.8% | 1.1% | -2.4% |
You may also like the below Video Courses
FAQ about JUBILANT PHARMOVA Financials
How the annual revenues of JUBILANT PHARMOVA have changed ?
The Revenues of JUBILANT PHARMOVA have increased by 2.47% YoY .
How the Earnings per Share (EPS) of JUBILANT PHARMOVA have changed?
The Earnings Per Share (EPS) of JUBILANT PHARMOVA has increased by Positive YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs